Nuwellis (NUWE) Registration Filing summary

Company overview and business model

• Focuses on medical technology for fluid overload, developing and commercializing ultrafiltration devices, notably the Aquadex System, for adult and pediatric patients unresponsive to diuretics.

• Aquadex System allows precise, safe fluid removal and is used in heart failure, kidney failure, and post-surgical care.

• Expanding into pediatric renal replacement therapy with a new device, Vivian, targeting commercialization in late 2025.

Financial performance and metrics

• As of June 28, 2024, public float was approximately $1.7 million, with 515,627 shares outstanding at $9.93 per share.

• Market value of outstanding common stock held by non-affiliates is below $75 million, qualifying as a smaller reporting company.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D, capital expenditures, working capital, and administrative expenses.